Features | Partner Sites | Information | LinkXpress
Sign In
Schiller
GLOBETECH PUBLISHING
Fluke Biomedical

Sarcopenia Can Predict Post-Hepatectomy Survival

By HospiMedica International staff writers
Posted on 03 Oct 2013
A new study suggests that sarcopenia can predict worse overall survival for hepatocellular carcinoma (HCC) following partial hepatectomy.

Researchers at Kyushu University (Fukuoka, Japan) retrospectively collected data for 186 consecutive patients who underwent hepatectomy for HCC with curative intent between January 2004 and December 2009. Patients were assigned to one of two groups according to the clinical presence or absence of sarcopenia. They were also assessed by computerized tomography (CT) measurement of muscle mass at the level of the third lumbar vertebra, and clinic-pathological, surgical outcome, and long-term survival data were analyzed.

The results showed that sarcopenia was present in 40.3% of the patients, and was significantly correlated with female sex, lower body mass index (BMI), and liver dysfunction, as indicated by abnormal serum albumin levels and indocyanine green retention test at 15-minute values. In patients with and without sarcopenia, the 5-year overall survival rate was 71% and 83.7% respectively, and the 5-year recurrence-free survival rate was 13% and 33.2% respectively. Analysis revealed that reduced skeletal muscle mass was also predictive of an unfavorable prognosis. The study was published in the October 2013 issue of the British Journal of surgery (BJS).

“The present study investigated the effect of sarcopenia on short- and long-term outcomes following partial hepatectomy for hepatocellular carcinoma, and aimed to identify prognostic factors,” said lead author Norifumi Harimoto, MD, PhD, and colleagues of the department of surgery and science. “Sarcopenia was predictive of worse overall survival, even when adjusted for other known predictors.”

Sarcopenia (from the Greek, meaning "poverty of flesh") is the degenerative loss of skeletal muscle mass. It is characterized first by muscle atrophy, along with a reduction in muscle tissue quality, caused by such factors as replacement of muscle fibers with fat, an increase in fibrosis, changes in muscle metabolism, oxidative stress, and degeneration of the neuromuscular junction. Combined, these changes lead to progressive loss of muscle function and frailty. Sarcopenia can thus be thought of as a muscular analog of osteoporosis, also caused by inactivity and counteracted by exercise. The combination of osteoporosis and sarcopenia results in the significant frailty often seen in the elderly population.

Related Links:

Kyushu University



Centurion Service
MinXray
Bovie Medical

Channels

Critical Care

view channel
Image: The Trellis peripheral infusion system (Photo courtesy of Covidien).

Thrombolytic Drug Delivery Device Dissolves Blood Clots

A redesigned peripheral infusion system enables focused treatment of blood clots to avoid potential post-thrombotic syndrome (PTS). The updated Trellis peripheral infusion system is a pharmacomechanical... Read more

Women's Health

view channel
Image: A prototype contraceptive implant (Photo courtesy of MicroCHIPS).

Contraceptive Implant Hails New Era of Birth Control

A fingernail-sized implant holds enough 30-microgram daily doses of levonorgestrel to provide contraception for 16 years. Developed by MicroCHIPS (Lexington, MA, USA), a MIT (Cambridge, MA, USA) startup,... Read more

Health IT

view channel
Image: The Health eResearch Center UV2 supercomputer (Photo courtesy of HeRC).

Supercomputer Accelerates Pace of Health Research

The University of Manchester (United Kingdom) is financing a new supercomputer system that can analyze bigger and more complex sets of information. The Health eResearch Center (HeRC; Manchester, United... Read more

Business

view channel

Spectranetics Completes Acquisition of AngioScore

Spectranetics (Colorado Springs, CO, USA) has completed the acquisition of AngioScore (Fremont, CA, USA), a leading developer, manufacturer, and marketer of cardiovascular specialty balloons. The transaction, for USD 230 million in cash and contingent commercial and regulatory milestone payments, will combine differentiated,... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.